The NICE British National Formulary (BNF) and British National Formulary for Children (BNFc) sites are only available to users in the UK, Crown Dependencies and British Overseas Territories. If you believe you are seeing this page in error please contact us. Clomipramine belongs to the class of medications known as tricyclic antidepressants. It is used to treat depression and obsessive-compulsive disorders (OCD). These disorders are related to imbalances of certain brain chemicals. This medication helps to reestablish balance to these chemicals. It may take several days to a few weeks to see a significant benefit. This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here.
Contents: Description Pharmacology Indications and Usage Contraindications Warnings Precautions Drug Interactions Adverse Reactions Overdose Dosage Supplied Anafranil patient information (in plain English) Suicidality in Children and Adolescents — Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Anafranil or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Anafranil is not approved for use in pediatric patients. Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. Download the complete FDA warning concerning antidepressant use in children and adults. Physicians use tricyclic antidepressants in the treatment of panic disorder, PTSD, generalized anxiety and depression that occurs with anxiety. If uncomfortable side effects appear, one approach is to wait two to three weeks for them to diminish before increasing to the next higher dose. The sedating side effects can limit productivity and concentration during the day. Of this family, imipramine has been the focus of most of the panic treatment research. Often effective in reducing panic attacks and elevating depressed mood. If the patient adjusts to the side effects, the physician increases the dosage every two or more days until the patient is taking the preferred dosage. One quarter to one half of imipramine patients relapse after tapering from the drug. Initial use of imipramine occasionally causes an increase in anxiety that usually diminishes in several weeks. Patients with certain abnormal electrocardiograms, with narrow-angle glaucoma, or with an enlarged prostate should not take this medication. Like imipramine, you may experience more general anxiety the first few days up to three weeks. Increase by 25 mg every three to four days to 100 mg per day, usually taken in one dose. Avoid during first three months of pregnancy and consult physician before using last six months and before breast-feeding. For this reason, the medication trial should probably be initiated with a very low dose -- as little as 10 to 25 milligrams (mg) per day of imipramine, for example. Typically taken in one dose at bedtime, but can be divided. Use during pregnancy or breast-feeding only after approval from your physician. Headache, drowsiness, dizziness, nervousness, trouble sleeping, dry mouth, nausea, vomiting, blurred vision, altered taste, sweating, stomach upset, constipation, loss of appetite, anxiety, or yawning may occur. Some people may experience side effects on dosages as low as 10 mg per day: jitteriness, irritation, unusual energy, and difficulty falling or staying asleep. One-third of panic-prone individuals become jittery and actually experience more anxiety symptoms for the first two to three weeks. The sedating side effects can limit productivity and concentration during the day. Consult your physician before using during pregnancy or breast-feeding. Start at 25 to 75 mg per day and increase over one or two weeks to an average dose of 75 to 150 mg and a maximum dose of 300 mg. Nausea and dizziness can be be common side effects. Some of these side effects will disappear with the passage of time or with a decrease in the dosage. The anticholinergic effects of dry mouth, blurred vision, constipation, and difficulty in urination; postural hypotension; tachycardia, loss of sex drive; erectile failure; increased sensitivity to the sun; weight gain; sedation (sleepiness); increased sweating. Men with an enlarged prostate should avoid certain antidepressants.
Indications, dose, contra-indications, side-effects, interactions, cautions, warnings and other safety information for CLOMIPRAMINE HYDROCHLORIDE. The recommended adult dose of clomipramine ranges from 25 mg to 200 mg daily in divided doses, preferably with meals and at bedtime. The dose depends on.